Head-To-Head Contrast: Osiris Therapeutics (OTCMKTS:OSIR) versus DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT) and Osiris Therapeutics (OTCMKTS:OSIR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Profitability

This table compares DBV Technologies and Osiris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-638.21%	-74.41%	-55.84%
Osiris Therapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares DBV Technologies and Osiris Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73 million	5.77	-$72.73 million	($0.84)	-1.12
Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A

Osiris Therapeutics has lower revenue, but higher earnings than DBV Technologies.

Analyst Ratings

This is a summary of recent recommendations and price targets for DBV Technologies and Osiris Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1	0	2	0	2.33
Osiris Therapeutics	0	0	0	0	N/A

DBV Technologies currently has a consensus price target of $4.00, indicating a potential upside of 325.53%. Given DBV Technologies’ higher possible upside, equities research analysts plainly believe DBV Technologies is more favorable than Osiris Therapeutics.

Institutional & Insider Ownership

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are held by institutional investors. 1.9% of DBV Technologies shares are held by company insiders. Comparatively, 43.4% of Osiris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Osiris Therapeutics

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.